# Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes

> **NCT00099853** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 362 (actual)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Vildagliptin
- **DRUG:** pioglitazone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00099853
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** 2008-01
- **Final completion:** 2008-01
- **Target enrollment:** 362 (ACTUAL)
- **Last updated:** 2020-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00099853

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00099853, "Efficacy and Safety of Vildagliptin in Combination With Pioglitazone in Patients With Type 2 Diabetes". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00099853. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*